SUNPHARMA - Sun Pharmaceutical Industries Ltd. Share Price

In the Q3 FY26 earnings call, Sun Pharmaceutical Industries Limited provided a positive outlook, highlighting strong sales growth, a robust balance sheet, and promising product launches. The company reported consolidated sales of Rs. 1,54,691 million for the quarter, a growth of 15.1% year-over-year. The executive team noted total sales growth, excluding milestone income, of 14.7%. The growth was fueled by a landmark income of US$55 million in the rest of the world.

Management pointed out the significant gross margin of 81%, attributed to an improved product mix, and an EBITDA of Rs. 49,485 million, reflecting a 23.4% increase compared to the previous year, with a margin of 31.9%. The reported net profit after tax was Rs. 33,688 million, a 16% increase, while the adjusted net profit stood at Rs. 35,367 million, up 9.9%. They declared an interim dividend of Rs. 11 per share.

Key forward-looking topics included:

1. Market Leadership: Sun Pharma retains the top position in India with an 8.4% market share, indicating potential for further growth aided by the anticipated launch of Semaglutide, with preparations already underway for field force expansion.
2. Innovative Medicines: The company expects continuous growth in its innovative medicines sector, particularly with new launches like UNLOXCYT and LEQSELVI, despite facing challenges in the generics market.
3. R&D Investments: Sun Pharma is committed to investing 5.8% of its sales towards R&D, with a focus on both innovative and generic therapeutics. They anticipate guiding on R&D spending for the upcoming fiscal year.
4. Acquisition Strategy: Management is open to tuck-in acquisitions in emerging markets to enhance growth while maintaining a disciplined approach to M&A.

This indicates management's strategic focus on sustainable growth, innovation, and market leadership, driven by promising products and robust financial health.

Major Questions and Answers from Sun Pharmaceutical's Q3 FY26 Earnings Call

Question 1: "Could you walk us through your M&A strategy and what you are hoping to target or achieve with the strategy? Are you looking at tuck-ins, biosimilars, or expanding geographic presence?"

Answer: "The US remains a critical focus for us, particularly for innovative medicines. We're also considering smaller acquisitions in emerging markets to enhance our scale. Our strategy is disciplined; acquisitions are only pursued if they align with our long-term growth objectives. We aim to grow organically and be an attractive investment opportunity while ensuring any potential acquisition integrates well without losing focus."

Question 2: "On the innovative medicines sales, ex the milestone payment, the growth has been a bit soft compared to earlier quarters. Can you elaborate on that?"

Answer: "The growth appears lower partly due to a high base from prior one-time sales to partners last year. However, our specialty segment should sustain good performance. I recommend evaluating our business on an annualized basis instead of strictly by quarterly results, as that offers a clearer picture of our progress."

Question 3: "R&D spend on the innovative portfolio has been decreasing lately. Could you explain that?"

Answer: "The reduction relates to timing in beginning clinical trials. We are initiating new trials, including for GL0034, which should increase our R&D spend moving forward. We will provide a clearer direction for R&D expenditure next quarter, aligning our investments with our ongoing projects and future growth."

Question 4: "On US sales, what do you see happening with the generics business excluding Revlimid? Is it stable?"

Answer: "Excluding Lenalidomide, the generics business shows a slight decrease due to heightened competition on specific products. We're optimistic about recovery as we anticipate compliance in our manufacturing sites, enabling new product launches soon."

Question 5: "How are you planning to support the new product launches like LEQSELVI and UNLOXCYT?"

Answer: "Spending on product launches is evenly split between LEQSELVI and UNLOXCYT. Launch expenses are increasing as we've recently launched UNLOXCYT. This will become a core part of our operational expenses moving forward to support market growth."

Question 6: "What is the status of your pipeline for GL0034 in diabetes? When can we expect new data?"

Answer: "We're presenting Phase-2a data for GL0034 at upcoming scientific conferences. Our current Phase-2b study should conclude within 12 to 18 months, at which point we expect to share more substantial results."

Question 7: "Regarding the gross margins, what key drivers should we consider for sustaining high levels beyond Revlimid?"

Answer: "Although we don't provide specific product margins, a better mix of products has positively impacted our gross margins compared to last year. We aim to maintain these levels by optimizing our product offering and focusing on our core strengths."

Question 8: "What is your plan for the upcoming Semaglutide launch in India, and will you add to your sales force for supporting this product?"

Answer: "We anticipate launching Semaglutide and will add some field force to support this product introduction. However, predicting exact growth rates is challenging as market conditions evolve."

Question 9: "With your interest in biosimilars, how are you approaching this area now compared to the past?"

Answer: "We're reevaluating our potential in biosimilars, considering regulatory changes and costs. Our decisions will be based on comprehensive assessments that include manufacturing capabilities, investments, and market returns."

Question 10: "What is the role of UNLOXCYT in your product strategy regarding patient demographics?"

Answer: "UNLOXCYT is primarily positioned for new patients, focusing on its unique efficacy and tolerability profile. While some patients may transition from other therapies, our initial target remains those starting on new treatments."